First US Trial to Test Aerosolized Chemo in Advanced Cancers First US Trial to Test Aerosolized Chemo in Advanced Cancers
A team of US researchers is investigating whether pressurized intraperitoneal aerosolized chemotherapy (PIPAC) can benefit patients with advanced cancer and peritoneal carcinomatosis.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 10, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Second-Look Surgery Plus Intraperitoneal Chemo No Benefit for Colorectal Metastases Second-Look Surgery Plus Intraperitoneal Chemo No Benefit for Colorectal Metastases
Second-look surgery plus oxaliplatin HIPEC is no better than standard surveillance at prolonging disease-free survival for patients with colorectal peritoneal metastases, a new study suggests.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 13, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Roche provides update on Phase III study of Tecentriq in women with advanced stage ovarian cancer
Basel, 13 July 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMagyn050 study showed that the addition of Tecentriq® (atezolizumab) to Avastin® (bevacizumab), paclitaxel and carboplatin did not meet its primary endpoint of progression-free survival (PFS) for the front-line treatment of women with newly diagnosed advanced stage ovarian cancer. Topline safety data indicate that safety for Tecentriq in combination with Avastin, paclitaxel and carboplatin was consistent with the known safety profile of the combination.“Ovarian cancer remains one of the most aggressive cancers a...
Source: Roche Investor Update - July 13, 2020 Category: Pharmaceuticals Source Type: news

Roche provides update on Phase III study of Tecentriq in women with advanced stage ovarian cancer
Basel, 13 July 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMagyn050 study showed that the addition of Tecentriq® (atezolizumab) to Avastin® (bevacizumab), paclitaxel and carboplatin did not meet its primary endpoint of progression-free survival (PFS) for the front-line treatment of women with newly diagnosed advanced stage ovarian cancer. Topline safety data indicate that safety for Tecentriq in combination with Avastin, paclitaxel and carboplatin was consistent with the known safety profile of the combination.“Ovarian cancer remains one of the most aggressive cancers a...
Source: Roche Media News - July 13, 2020 Category: Pharmaceuticals Source Type: news

CRC With Peritoneal Metastases: CRS-HIPEC Refinements CRC With Peritoneal Metastases: CRS-HIPEC Refinements
Refinements to the treatment pathway may improve overall survival in patients with colorectal cancer who have peritoneal metastases, suggest four new studies.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 7, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

FDA Approves Olaparib/Bevacizumab Maintenance FDA Approves Olaparib/Bevacizumab Maintenance
The FDA has announced a new approved indication for olaparib in adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 12, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

FDA approves olaparib plus bevacizumab as maintenance treatment for ovarian, fallopian tube, or primary peritoneal cancers
Hematology / Oncology Drug Approvals (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - May 11, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Approves Expanded Olaparib Indication to Include Combination with Bevacizumab
The FDA expanded the indication of olaparib to include a combination regimen with bevacizumab for the first-line maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. (Source: CancerNetwork)
Source: CancerNetwork - May 8, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

FDA Approves Niraparib for Advanced Ovarian Cancer
The FDA approved niraparib for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy. (Source: CancerNetwork)
Source: CancerNetwork - April 29, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Ovarian cancer: recognition and initial management [CG122], NICE (Published 27th April)
This guideline covers detecting, diagnosing and treating women (18 years and older) who have, or are suspected of having, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer or borderline ovarian cancer. It aims to enable earlier detection of ovarian cancer and improve initial treatment. This guideline was previously called ovarian cancer: the recognition and initial management of ovarian cancer. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - April 27, 2020 Category: Consumer Health News Source Type: news

FDA D.I.S.C.O.: Niraparib in Ovarian Cancer Transcript
FDA medical oncologists discuss the agency ’s March 2017 approval of niraparib for the maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 28, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Janssen to Highlight Depth of Solid Tumor Portfolio at ASCO GU
RARITAN, N.J., February 3, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple data presentations from a robust solid tumor portfolio that will be featured at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place February 13-15 in San Francisco. Company-sponsored data presentations will include clinical results for ERLEADA® (apalutamide) and niraparib in prostate cancer; and BALVERSA™ (erdafitinib) in bladder cancer. “We are committed to improving outcomes in patients with prostate and bladder cancer where high unmet...
Source: Johnson and Johnson - February 3, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Niraparib for Advanced Ovarian Cancer with HRD+ Status Approved by FDA
Niraparib was approved by the (FDA) for previously treated advanced ovarian, fallopian, or primary peritoneal cancers. (Source: CancerNetwork)
Source: CancerNetwork - October 23, 2019 Category: Cancer & Oncology Authors: Seth Augenstein Source Type: news

Surgery for Intraperitoneal Metastases From Lung Cancer Surgery for Intraperitoneal Metastases From Lung Cancer
This case series demonstrates that cytoreductive surgery for diffused peritoneal metastases from lung cancer can yield improved prognosis and long-term survival.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 16, 2019 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news

Can PARP Inhibitors and Immune Checkpoint Inhibitors Improve Outcomes in Ovarian Cancer?
A new phase 1a/b study examined a total of 49 patients with solid tumors, including 34 with ovarian, fallopian tube, or primary peritoneal cancer, treated with a combination of the PARP 1/2 inhibitor pamiparib and the anti-PD-1 monoclonal antibody tislelizumab in several dose escalation cohorts. (Source: CancerNetwork)
Source: CancerNetwork - August 23, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Australian Study Shows Treatment Advances for Peritoneal Mesothelioma
Patients with peritoneal mesothelioma undergoing a second cytoreductive surgery had a median survival of 92 months, according to a recent study at St. George Hospital and the University of South Wales in Sydney, Australia. That same group of patients also had a five-year survival rate of 71.8%, further illustrating the progress being made in treating the peritoneal subtype of this rare and aggressive cancer. The Journal of Surgical Oncology published the study in July 2019. The single-center study detailed the survival benefits of cytoreduction and perioperative intraperitoneal chemotherapy in colorectal, ovarian, appendic...
Source: Asbestos and Mesothelioma News - August 12, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Discouraging OS Results With Bevacizumab in Ovarian Cancer
Long-term follow-up of a phase III trial showed overall survival results for bevacizumab plus chemotherapy in women with ovarian, fallopian tube, or primary peritoneal cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 26, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Peritoneal Carcinomatosis Profiles Highlight Gastric Cancer Targets Peritoneal Carcinomatosis Profiles Highlight Gastric Cancer Targets
Sequencing of whole exome and transcriptome of peritoneal carcinomatosis (PC) in patients with gastric adenocarcinoma (GAC) has given novel insights and opened up new therapeutic opportunities, according to Texas-based researchers.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 22, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Novel Imaging May Make Peritoneal Mesothelioma Surgery More Effective
Dr. James Cusack at Massachusetts General Hospital has begun using a novel imaging system for patients with peritoneal mesothelioma that could better identify tumor cells during surgery, reducing the chance of recurrence. Cusack, an associate professor of surgery at the Harvard University Medical School, is also studying the molecular imaging technology with select cases of appendiceal, ovarian and gastrointestinal cancers. The single-center clinical trial, which started April 3, aims to determine safety and efficacy of the procedure for peritoneum metastases, according to Cusack. The Lumicell System already has been studi...
Source: Asbestos and Mesothelioma News - May 6, 2019 Category: Environmental Health Authors: Daniel King Source Type: news

Smart nanoparticles help improve treatment of peritoneal tumors
(Estonian Research Council) Research carried out at the University of Tartu Faculty of Medicine used nanoparticles for the development of new imaging and treatment methods for peritoneal cancers. Tests showed that precision-guided anticancer nanoparticles have improved efficacy and reduced side effects. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 22, 2019 Category: International Medicine & Public Health Source Type: news

Lab-grown mini tumors could help identify personalized treatments for people with rare cancers
UCLA scientists have developed a new method to quickly screen hundreds of drugs in order to identify treatments that can target specific tumors.The approach could help scientists understand how a person ’s tumor would respond to a certain drug or drug combination, and it could help guide treatment decisions for people with rare and hard-to-treat cancers. Apaper detailing the new technique was published in Communications Biology.“We always focus on how we need new and better drugs to treat cancer,” said Alice Soragni, the senior author of the study and a scientist at the UCLA Jonsson Comprehensive Can...
Source: UCLA Newsroom: Health Sciences - February 25, 2019 Category: Universities & Medical Training Source Type: news

New recommendations say not all women need genetic testing for cancer. Critics say it could cost lives
Primary care providers should screen women for personal, family and/or ethnic history of breast, ovarian, tubal or peritoneal cancer to decide who should undergo genetic counseling for BRCA1 and BRCA2 mutations, the US Preventive Services Task Force recommended Tuesday. The mutations increase a woman's cancer risk. (Source: CNN.com - Health)
Source: CNN.com - Health - February 19, 2019 Category: Consumer Health News Source Type: news

Cytoreductive Surgery/HIPEC: Safer for Peritoneal Metastases? (CME/CE)
(MedPage Today) -- Study shows lower infection, 30-day mortality vs other high-risk procedures, but experts question validity of comparisons (Source: MedPage Today Surgery)
Source: MedPage Today Surgery - January 18, 2019 Category: Surgery Source Type: news

Living With Cancer: Ovarian cancer risk after hysterectomy
Ovarian cancer risk after hysterectomy? If you've had a hysterectomy, your risk of developing ovarian cancer or primary peritoneal cancer,?a type of cancer that acts like ovarian cancer, depends on the type of hysterectomy you had.?Learn more from Dr. Yvonne Butler Tobah, a Mayo Clinic OB-GYN Monoclonal antibody drugs for cancer? Monoclonal antibody drugs use [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - January 11, 2019 Category: Databases & Libraries Source Type: news

Role of PARP Inhibitors in BRCA-Related Malignancies Role of PARP Inhibitors in BRCA-Related Malignancies
Review the pharmacology of PARP inhibitors and their use in BRCA-mutated malignancies including breast, ovarian, fallopian tube, and primary peritoneal cancers.U.S. Pharmacist (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 6, 2018 Category: Consumer Health News Tags: Pharmacist Journal Article Source Type: news

Ovarian Epithelial Fallopian Tube Cancer Treatment
Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - July 26, 2018 Category: General Medicine Source Type: news

Noninferiority of Neoadjuvant Chemo Cannot Be Confirmed in Ovarian Cancer Trial
Dave LevitanJun 6, 2018The noninferiority of neoadjuvant chemotherapy vs upfront surgery could not be confirmed with regard to overall survival in patients with ovarian, tubal, and peritoneal cancers. (Source: CancerNetwork)
Source: CancerNetwork - June 6, 2018 Category: Cancer & Oncology Authors: A Source Type: news

Hot Chemo Fails in Rare Cancer
(MedPage Today) -- HIPEC and surgery equals surgery alone in peritoneal carcinomatosis (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - June 4, 2018 Category: Gastroenterology Source Type: news

No OS Benefit From HIPEC in Colorectal Cancer
Bryant FurlowJun 4, 2018Overall, patients with mCRC and isolated peritoneal carcinomatosis did not benefit when hyperthermic intraperitoneal chemotherapy was added to surgery. (Source: CancerNetwork)
Source: CancerNetwork - June 4, 2018 Category: Cancer & Oncology Authors: A Source Type: news

FDA Approves Rucaparib for Recurrent Ovarian Cancer Maintenance Therapy
The FDA has granted approval of rucaparib for maintenance therapy in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. (Source: CancerNetwork)
Source: CancerNetwork - April 11, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Gynecologic Cancers SiteTerms/www.cannabissciencetech.com/News Ovarian Cancer Source Type: news

Clovis Oncology ovarian cancer drug receives fast-tracked FDA approval
Clovis Oncology won the fast-tracked verdict it hoped for on Friday when the  U.S. Food and Drug Administration approved marketing the company's ovarian cancer drug rucaparib to treat a broader range of patients. The FDA approved the Boulder-based company (Nasdaq: CLVS) selling rucaparib as a maintenance treatment in women “with recurrent epithelial ovarian, fallopian tu be, or primary peritoneal cancer who are platinum sensitive” and regardless of their genetic profile. The FDA completed its… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - April 6, 2018 Category: American Health Authors: Greg Avery Source Type: news

Clovis Oncology ovarian cancer drug receives fast-tracked FDA approval
Clovis Oncology won the fast-tracked verdict it hoped for on Friday when the  U.S. Food and Drug Administration approved marketing the company's ovarian cancer drug rucaparib to an expanded range of patients. The FDA approved the Boulder-based company (Nasdaq: CLVS) selling rucaparib as a maintenance treatment in women “with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are platinum sensitive” and regardless of their genetic profile. That means more women with… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 6, 2018 Category: Biotechnology Authors: Greg Avery Source Type: news

Dr. Nita Ahuja appointed the Carmalt Professor of Surgery
Ahuja is a surgeon and research scientist internationally renowned for her expertise in the management of peritoneal cancer metastases. (Source: Yale Science and Health News)
Source: Yale Science and Health News - March 22, 2018 Category: Universities & Medical Training Source Type: news

Quiz: Genetic Risk Evaluation for Fallopian Tube Cancer?
Should a patient with fallopian tube cancer undergo genetic risk evaluation? What is essential in post-treatment monitoring of ovarian, fallopian tube, and primary peritoneal cancers? Take this multiquestion quiz to find out.   (Source: CancerNetwork)
Source: CancerNetwork - March 20, 2018 Category: Cancer & Oncology Authors: Bryant Furlow Tags: Gynecologic Cancers Quiz Source Type: news

Activity matters: How Fitbit can help us understand cancer surgery recovery
(Oxford University Press USA) A new study published in Annals of Behavioral Medicine finds that more activity during inpatient recovery predicted lower risk of 30- and 60-day readmission after surgery for metastatic peritoneal cancer. By monitoring patients using Fitbit, researchers found that higher Fitbit steps forecast better patient outcomes. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 6, 2017 Category: Cancer & Oncology Source Type: news

Clovis Oncology gets FDA fast-tracked review date for ovarian cancer drug
The U.S. Food and Drug Administration has granted a fast-tracked review of using a Clovis Oncology drug to treat a wider range of ovarian cancer patients. The Boulder-based company (Nasdaq: CLVS) seeks approval to use its ovarian cancer drug, rucaparib, as a maintenance treatment in women “with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are platinum sensitive” and regardless of their genetic profile. The FDA says it will make a decision by April 6, 2018,… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 6, 2017 Category: Biotechnology Authors: Greg Avery Source Type: news

Clovis Oncology gets FDA fast-tracked review date for ovarian cancer drug
The U.S. Food and Drug Administration has granted a fast-tracked review of using a Clovis Oncology drug to treat a wider range of ovarian cancer patients. The Boulder-based company (Nasdaq: CLVS) seeks approval to use its ovarian cancer drug, rucaparib, as a maintenance treatment in women “with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are platinum sensitive” and regardless of their genetic profile. The FDA says it will make a decision by April 6, 2018,… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 6, 2017 Category: Pharmaceuticals Authors: Greg Avery Source Type: news

Is Peritoneal Cancer Hereditary?
Title: Is Peritoneal Cancer Hereditary?Category: Doctor's& Expert's views on SymptomsCreated: 10/13/2017 12:00:00 AMLast Editorial Review: 10/13/2017 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - October 13, 2017 Category: Cancer & Oncology Source Type: news

Ovarian Fallopian Tube Primary Peritoneal Cancer
Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Prevention (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - July 27, 2017 Category: General Medicine Source Type: news

ovarian epithelial fallopian cancer
Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - July 27, 2017 Category: General Medicine Source Type: news

HIPEC for Colorectal Cancer With Peritoneal Carcinomatosis
This video reviews the use of hyperthermic intraperitoneal chemotherapy with cytoreductive surgery in colorectal cancer with peritoneal carcinomatosis. (Source: CancerNetwork)
Source: CancerNetwork - May 15, 2017 Category: Cancer & Oncology Authors: Hans Schlitt, MD Tags: Videos Gastrointestinal Cancers Source Type: news

Case: Coccidioidomycosis Mimicking Peritoneal Carcinomatosis Case: Coccidioidomycosis Mimicking Peritoneal Carcinomatosis
New onset ascites, lymphadenopathy, and peritoneal nodules suggested a metastatic carcinomatosis in this patient; but her residence in Arizona provided the key to the correct diagnosis.Applied Radiology (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - May 8, 2017 Category: Radiology Tags: Radiology Journal Article Source Type: news

New Approaches Needed for Peritoneal Metastases in CRC New Approaches Needed for Peritoneal Metastases in CRC
Dr David Kerr challenges the oncology community to come up with rational, meaningful clinical trials to clarify the biology of metastatic peritoneal disease in colorectal cancer.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 13, 2017 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

FDA Approves Niraparib for Recurrent Ovarian Cancer
The FDA announced the approval of niraparib, an oral PARP inhibitor, for the treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. (Source: CancerNetwork)
Source: CancerNetwork - March 28, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Gynecologic Cancers News Ovarian Cancer Source Type: news

FDA approves maintenance treatment for recurrent epithelial ovarian, fallopian tube or primary peritoneal cancers
The U.S. Food and Drug Administration today approved Zejula (niraparib) for the maintenance treatment (intended to delay cancer growth) of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, whose tumors have completely or partially shrunk (complete or partial response, respectively) in response to platinum-based chemotherapy. (Source: Food and Drug Administration)
Source: Food and Drug Administration - March 27, 2017 Category: American Health Source Type: news

Maintenance Chemo After CR Fails to Extend Survival in Ovarian Cancer
A long-term phase III trial found that maintenance chemotherapy did not improve overall survival over surveillance among women with advanced ovarian/fallopian tube/peritoneal cancer who had a complete response to first-line therapy. (Source: CancerNetwork)
Source: CancerNetwork - March 14, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Gynecologic Cancers News Ovarian Cancer Conferences/SGO 2017 Source Type: news

Low Recurrence After Risk-Reducing Surgery for BRCA Carriers Low Recurrence After Risk-Reducing Surgery for BRCA Carriers
Dr Maurie Markman discusses the results of an RRSO surgery study showing a 1% incidence rate in long-term follow-up of subsequent peritoneal cancer.Medscape Oncology (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - February 24, 2017 Category: Surgery Tags: Hematology-Oncology Commentary Source Type: news

Bevacizumab Approved for Another Type of Ovarian Cancer Bevacizumab Approved for Another Type of Ovarian Cancer
The latest FDA approval is for use in patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 12, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Roche's Avastin (bevacizumab) plus chemotherapy receives FDA approval for platinum-sensitive recurrent ovarian cancer
Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced that the U.S. Food and Drug Administration (FDA) has approved Avastin® (bevacizumab), either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine chemotherapy, followed by Avastin alone, for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. (Source: World Pharma News)
Source: World Pharma News - December 9, 2016 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news